T
Turbine AI
Simulation-driven drug discovery company delivering population targeted cancer therapies
About Turbine AI
Turbine AI has developed a cell simulation platform that uses machine learning to model human biology and predict the effectiveness of cancer treatments. This technology, called Simulated Cells™, aims to improve the drug discovery and development process by identifying promising therapeutic targets and patient populations that are most likely to respond to treatment.
Read full description
The company collaborates with pharmaceutical companies, such as AstraZeneca, to apply its simulation platform to specific challenges in oncology, like understanding drug resistance in hematological cancers. By simulating how cancer cells behave at a molecular level, Turbine AI can provide insights that are difficult to obtain through traditional laboratory experiments alone.
The platform is designed to de-risk drug development, potentially reducing the time and cost associated with bringing new therapies to market. The company offers a "Virtual Lab" for potential clients to explore the technology's capabilities.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Budapest, Hungary
- Employees
- 116
- Open positions
- 3
- Dealroom signal
- 86.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biomarkers, Neurology
- Technology
- Artificial Intelligence, Hardware, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2026 | $23M | $93M | Beiersdorf · Accel · Mercia Asset Management · MSD Global Health Innovation Fund | ↗ |
| LATE VCOther financing | May 2024 | $0 | — | Accenture Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Turbine AI is 10K monthly website visits, up 0% over the last three months. Turbine AI's team grew 12.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Series A8 investors entered at this stage
Day One Capital
Mercia Asset Management
Merck & Co.
XTX Ventures
MassMutual Ventures
Interactive Venture Partners
Beiersdorf
MSD Global Health Innovation Fund
Series B and later2 investors entered at this stage
AI Fund
Accenture Ventures
Other known investors2 additional known investors
Budapest University of Technology and Economics
EIT Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Turbine AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Turbine AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.